BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1190 related articles for article (PubMed ID: 11503270)

  • 1. [Clinical application of cyclooxygenase-2 inhibitors].
    Dzielska-Olczak M; Olczak S
    Pol Merkur Lekarski; 2001 Jun; 10(60):480-2. PubMed ID: 11503270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays.
    Riendeau D; Charleson S; Cromlish W; Mancini JA; Wong E; Guay J
    Can J Physiol Pharmacol; 1997 Sep; 75(9):1088-95. PubMed ID: 9365818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of NSAIDs for the chemoprevention of colorectal cancer.
    Herendeen JM; Lindley C
    Ann Pharmacother; 2003 Nov; 37(11):1664-74. PubMed ID: 14565811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacology of selective COX-2 inhibitors.
    Capone ML; Tacconelli S; Sciulli MG; Patrignani P
    Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):49-58. PubMed ID: 14552704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclooxygenase-2 inhibitors: promise or peril?
    Mengle-Gaw LJ; Schwartz BD
    Mediators Inflamm; 2002 Oct; 11(5):275-86. PubMed ID: 12467519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COX-2-selective inhibitors (COXIBs): gastrointestinal safety.
    Pronai L; Hritz I; Molnar B; Herszenyi L; Tulassay Z
    Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):23-30. PubMed ID: 14552701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors.
    Kusunoki N; Yamazaki R; Kawai S
    Arthritis Rheum; 2002 Dec; 46(12):3159-67. PubMed ID: 12483719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New NSAIDs and gastroduodenal damage.
    Folco GC
    Ital J Gastroenterol; 1996 Dec; 28 Suppl 4():28-9. PubMed ID: 9032579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of colorectal cancer through the use of COX-2 selective inhibitors.
    Peek RM
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S50-6. PubMed ID: 15309515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors.
    Reddy BS; Rao CV
    J Environ Pathol Toxicol Oncol; 2002; 21(2):155-64. PubMed ID: 12086402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical data on COX-1 and COX-2 inhibitors: what possible alerts in pharmacovigilance?].
    Larousse C; Veyrac G
    Therapie; 2000; 55(1):21-8. PubMed ID: 10859997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COX-2-specific inhibition: implications for clinical practice.
    Pascucci RA
    J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S18-22. PubMed ID: 10643177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
    Sengupta S; Sellers LA; Cindrova T; Skepper J; Gherardi E; Sasisekharan R; Fan TP
    Cancer Res; 2003 Dec; 63(23):8351-9. PubMed ID: 14678996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention.
    Kismet K; Akay MT; Abbasoglu O; Ercan A
    Cancer Detect Prev; 2004; 28(2):127-42. PubMed ID: 15068837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cyclooxygenase(COX)-2-inhibition in the prevention and treatment of colorectal carcinoma].
    Tuynman JB; Hulscher JB; Steller EP; van Lanschot JJ; Richel DJ
    Ned Tijdschr Geneeskd; 2003 Nov; 147(45):2207-12. PubMed ID: 14640057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COX-2 inhibitors. What is their place?
    McGettigan P
    Aust Fam Physician; 2000 Sep; 29(9):847-52. PubMed ID: 11008387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 (COX-2) inhibitors: indications and complications.
    Pascucci RA
    J Am Osteopath Assoc; 2002 Sep; 102(9):487-9. PubMed ID: 12361181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity].
    Dammann HG
    Z Gastroenterol; 1999 Jan; 37(1):45-58. PubMed ID: 10091284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COX-1 and COX-2 inhibitors.
    Hawkey CJ
    Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):801-20. PubMed ID: 11566042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoprevention of gastrointestinal malignancies with nonsteroidal antiinflammatory drugs.
    Shaheen NJ; Straus WL; Sandler RS
    Cancer; 2002 Feb; 94(4):950-63. PubMed ID: 11920463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.